Literature DB >> 9537860

Characteristics of patients with dual infection by hepatitis B and C viruses.

J P Zarski1, B Bohn, A Bastie, J M Pawlotsky, M Baud, F Bost-Bezeaux, J Tran van Nhieu, J M Seigneurin, C Buffet, D Dhumeaux.   

Abstract

BACKGROUND/AIMS: The purpose of this study was to compare the epidemiological, biochemical, virological and histological characteristics of patients with chronic hepatitis B and C with those of patients suffering from chronic hepatitis C alone.
METHODS: Twenty-three patients with chronic hepatitis C, who were anti-HCV positive and HBs antigen positive, were studied and subdivided into two groups according to the presence or absence of HBV DNA replication. They were compared to 69 age- and sex-matched patients with chronic hepatitis who were anti-HCV positive and HBs antigen negative. All patients were HCV RNA positive by PCR, anti-HIV negative and anti-HDV negative. HBV DNA and HCV RNA were detected in serum by means of a branched DNA assay and PCR. The HCV serotypes were determined by the Chiron Riba HCV serotyping SIA technique. The histological characteristics included the Knodell score.
RESULTS: Epidemiological, biochemical and virological parameters were not different between the two groups. Only the prevalence of cirrhosis was greater in chronic hepatitis B and C patients than in patients with chronic hepatitis C alone (p = 0.01). Among chronic hepatitis B and C patients, HCV RNA level was significantly lower in HBV DNA positive than in HBV DNA negative patients (p = 0.01). Indeed, histological lesions were more severe in HBV DNA positive than in HBV DNA negative patients, including prevalence of cirrhosis (p = 0.01), Knodell score (p = 0.05) and, among the latter, piecemeal necrosis (p = 0.01) and fibrosis (p = 0.05). The characteristics of patients with dual infection did not differ according to the mode of contamination and duration of HBV disease, except for a shorter duration in patients contaminated by drug abuse than in other patients.
CONCLUSIONS: These results suggest that HBV DNA replication inhibits HCV RNA replication in patients with chronic active hepatitis B and C but increases the severity of histological lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537860     DOI: 10.1016/s0168-8278(98)80198-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  75 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study.

Authors:  Paula J Lum; Kristen C Ochoa; Judith A Hahn; Kimberly Page Shafer; Jennifer L Evans; Andrew R Moss
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

3.  Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case-control study.

Authors:  Naser Ebrahimi Daryani; Mohsen Nassiri-Toosi; Armin Rashidi; Iman Khodarahmi
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

4.  Biological impact of hepatitis B virus X-hepatitis C virus core fusion gene on human hepatocytes.

Authors:  Zhen Ma; Qin-Hai Shen; Guo-Min Chen; Da-Zhi Zhang
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

5.  Hepatitis C virus (HCV) and hepatitis B virus (HBV) can coinfect the same hepatocyte in the liver of patients with chronic HCV and occult HBV infection.

Authors:  E Rodríguez-Iñigo; J Bartolomé; N Ortiz-Movilla; C Platero; J M López-Alcorocho; M Pardo; I Castillo; V Carreño
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 6.  Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.

Authors:  Jacinta A Holmes; Ming-Lung Yu; Raymond T Chung
Journal:  Expert Opin Drug Saf       Date:  2017-05-19       Impact factor: 4.250

7.  Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.

Authors:  Jonathan P Moorman; Chun L Zhang; Lei Ni; Cheng J Ma; Ying Zhang; Xiao Y Wu; Penny Thayer; Tareq M Islam; Thomas Borthwick; Zhi Q Yao
Journal:  Vaccine       Date:  2011-03-03       Impact factor: 3.641

8.  Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area.

Authors:  Chun-Lei Fan; Lai Wei; Dong Jiang; Hong-Song Chen; Yan Gao; Ruo-Bing Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  Tim-3 alters the balance of IL-12/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection.

Authors:  Jia M Wang; Cheng J Ma; Guang Y Li; Xiao Y Wu; Penny Thayer; Pamela Greer; Ashley M Smith; Kevin P High; Jonathan P Moorman; Zhi Q Yao
Journal:  Vaccine       Date:  2013-03-14       Impact factor: 3.641

10.  Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis.

Authors:  Erik Seth Kramer; Charlotte Hofmann; Paula G Smith; Mitchell L Shiffman; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.